Wegovy Pill vs Injection and Foundayo (Orforglipron): How Much Weight Do People Lose?

Foundayo (orforglipron) and the Wegovy pill (oral semaglutide) both lead to meaningful weight loss in trials, but more people land below 10% than on the injections. Matthew Weiner, MD, explains the trial numbers, the doses behind them and how to tell a poor, typical or super response.
How much weight do people lose on the Wegovy pill and Foundayo (orforglipron)?
In the trial behind the 25 mg Wegovy pill, people lost an average of 13.6% of their body weight over 64 weeks, and about 4 in 10 lost less than 10%. In the main trial behind Foundayo (orforglipron) at its highest strength, 17.2 mg, people lost about 11% on average over 72 weeks, and about 45% lost less than 10%. Both pills help most people lose weight, and both leave more people below 10% than the leading GLP-1 injections do.
These figures count everyone who was randomized in each trial, so they describe what happened to a large group of people and do not predict what any one person will lose. Matthew Weiner, MD, uses them as a yardstick, the same way he does in Is My GLP-1 Weight Loss Normal?. They show where most people land on each pill, and they make it easier to see whether a given result sits in the expected range or well outside it.
Key takeaways
- The Wegovy pill and Foundayo use one grading rule at any strength: under 10% of body weight lost is a poor response, over 25% is a super response, and anything in between is a typical response.
- About 4 in 10 people on the 25 mg Wegovy pill and nearly half on Foundayo 17.2 mg lose less than 10% in trials, compared with about 3 in 10 on the Wegovy 2.4 mg injection, about 1 in 5 on the Wegovy 7.2 mg injection and about 1 in 6 on Zepbound 15 mg.
- Early results should be judged against the time curve. On the Wegovy pill, the average person has reached roughly a third of a year's loss by 3 months.
- A poor response on a pill is a biology question to take to a provider, and an injectable medication may be worth discussing.
Wegovy pill vs injection: which leads to more weight loss?
The Wegovy pill and the Wegovy injection contain the same drug, semaglutide, but their trial results differ. On the 25 mg pill, about 40% of people lost less than 10% of their weight. On the 2.4 mg weekly injection, about 28% to 34% did, and on the newer 7.2 mg injection about 20% did. Tirzepatide 15 mg (Zepbound), a different weekly injection, left about 17% of people below 10%. Our Zepbound and Wegovy weight loss by dose guide has the full injection numbers.
| Medication and dose | How it is taken | Trial length | Share who lost less than 10% |
|---|---|---|---|
| Tirzepatide 15 mg (Zepbound) | Weekly injection | 72 weeks | About 17% |
| Semaglutide 7.2 mg (Wegovy injection) | Weekly injection | 72 weeks | About 20% |
| Semaglutide 2.4 mg (Wegovy injection) | Weekly injection | 68 to 72 weeks | About 28% to 34% |
| Semaglutide 25 mg (Wegovy pill) | Daily pill | 64 weeks | About 40% |
| Orforglipron 17.2 mg (Foundayo) | Daily pill | 72 weeks | About 45% |
Matthew Weiner, MD, reads this as a consistent pattern: the GLP-1 pills produce more poor responders than the injections. The comparison has limits. These numbers come from separate trials with different lengths and different groups of people, so they show the general picture rather than a head-to-head result. Still, for someone choosing between a pill and a shot, the gap in poor responders is the single most useful number to know, and it is a theme we also covered in best GLP-1 for weight loss: oral vs injectable semaglutide.
The 7.2 mg dose of the Wegovy injection matters for this comparison. In the trial that compared 7.2 mg with 2.4 mg, about 31% of people on 7.2 mg lost 25% or more of their weight, a level neither pill's trial reports. For someone weighing the strongest semaglutide option, that is the dose to compare against, and Wegovy vs Zepbound: should you switch? covers when moving between injections makes sense.
Foundayo vs Wegovy pill vs Zepbound: how do the results compare?
On the trial numbers, the 25 mg Wegovy pill produced somewhat more weight loss than Foundayo at 17.2 mg. The Wegovy pill averaged 13.6% over 64 weeks, with 27.9% of people losing 20% or more. Foundayo averaged about 11% over 72 weeks, with 18.4% losing 20% or more. These were separate trials, so the comparison is indirect.
| Measure | Wegovy pill 25 mg | Foundayo 17.2 mg |
|---|---|---|
| Trial and length | OASIS 4, 64 weeks | ATTAIN-1, 72 weeks |
| Average weight lost | 13.6% | About 11% |
| Lost less than 10% (poor) | About 40% | About 45% |
| Lost 20% or more | 27.9% | 18.4% |
| Lost more than 25% (super) | Not reported, below 27.9% | Not reported, below 18.4% |
Compared with Zepbound, Foundayo leaves far more people in the poor range: about 45% below 10% on Foundayo 17.2 mg, against about 17% on tirzepatide 15 mg. On average, the injections have produced larger results in trials, as our article on expected weight loss on semaglutide also shows. For people who strongly prefer a daily pill, that preference is worth weighing against the higher chance of a smaller result.
What counts as a poor, typical or super response on a GLP-1 pill?
Matthew Weiner, MD, grades a GLP-1 response by the percent of total body weight lost. For the Wegovy pill and Foundayo, the practice uses one rule at any strength: losing less than 10% is a poor response, losing more than 25% is a super response, and everything in between is a typical response. To find the percent, divide the pounds lost by the starting weight. Someone who started at 220 pounds and has lost 22 pounds has lost 10%.
| Grade | Weight lost at about a year | How common in the trials |
|---|---|---|
| Poor | Less than 10% | About 40% on the Wegovy pill 25 mg, about 45% on Foundayo 17.2 mg |
| Typical | 10% to 25% | Most of the remaining people |
| Super | More than 25% | Not reported for either pill, and smaller than the share who lost 20% or more |
Neither pill's trial reports how many people lost more than 25%. Because 27.9% of people on the Wegovy pill and 18.4% on Foundayo lost 20% or more, the share above 25% has to be smaller than those numbers. Super responders do exist on the pills, but they are less common than on the strongest injections.
The same rule applies at every pill strength because the lower tablet strengths are steps on the way up to the full dose. The cutoffs are practice definitions built on 64 to 72 week trials, and the practice's GLP-1 super responder check applies them to a person's drug, dose and time on treatment.
Is your GLP-1 weight loss on track?
Free 1-minute check. See how your weight loss compares with clinical trial results for your medicine, dose and time on it.
How much weight can you lose on the Wegovy pill in the first month?
Usually less than people expect, and that is normal. GLP-1 weight loss builds over about a year, and most of the first 3 months is spent stepping up the dose. Read from the trial curves, the average person on the Wegovy pill has reached a little over a tenth of a year's loss at 1 month, a bit more than a third at 3 months and nearly three quarters at 6 months. The practice starts grading results at 1 month, measured against this curve, and treats them as provisional until about a year.
| Time on the Wegovy pill | Share of a year's loss reached, on average | Average loss at that point | Poor response below | Super response above |
|---|---|---|---|---|
| 1 month | About 12% | About 1.6% | About 1.2% | About 3% |
| 3 months | About 37% | About 5% | About 3.7% | About 9% |
| 6 months | About 72% | About 10% | About 7% | About 18% |
| About a year | Nearly all of it | 13.6% | 10% | 25% |
A person who started at 200 pounds and is down 3 pounds after the first month on the Wegovy pill has lost 1.5%, which sits in the typical range on this curve. These are averages read from trial figures, so a single month on the scale says little on its own. The pills tend to reach their plateau a little sooner than the highest injectable doses, which is why a larger share of the eventual loss shows up in the first 6 months. The GLP-1 weight loss calculator shows what the trials predict over a full year.
Foundayo dosage chart and Wegovy pill doses: which strength do the results apply to?
Foundayo tablets come in strengths from 0.8 mg up to 17.2 mg. The trials that tested orforglipron used an earlier capsule form, and Lilly reports that capsule doses of 1, 3, 6, 12, 24 and 36 mg are equivalent to tablet doses of 0.8, 2.5, 5.5, 9, 14.5 and 17.2 mg. That equivalence is how the trial results carry over to the tablets prescribed today.
| Foundayo tablet | Equivalent trial capsule | Trial results available |
|---|---|---|
| 0.8 mg | 1 mg | No, lowest strength |
| 2.5 mg | 3 mg | No |
| 5.5 mg | 6 mg | Yes |
| 9 mg | 12 mg | Yes |
| 14.5 mg | 24 mg | No |
| 17.2 mg | 36 mg | Yes, highest strength and the dose behind the main results in this article |
For someone on Foundayo 0.8 mg, very little change in the first weeks is expected. The lower strengths are steps toward a full dose, and the prescriber sets the pace of each step based on response and side effects, as our guide to managing GLP-1 shot side effects explains.
The Wegovy pill follows the same idea. It starts at a lower strength and steps up to 25 mg, which is the only maintenance dose and the dose behind the 13.6% average. The lower Wegovy pill strengths are part of the climb and are not meant to be judged as a final result.
How much do the Wegovy pill, Foundayo and the injections cost without insurance?
As of November 2026, self-pay prices are $149 for the 1.5 mg Wegovy pill, $199 for 4 mg and $299 for the 9 and 25 mg strengths, and Foundayo runs $149 to $299 depending on the dose. For comparison, the Wegovy pen is $349 at 1 to 2.4 mg and Wegovy 7.2 mg is $399. Prices change often, and current introductory offers end December 31, 2026, so check the price before you start. Our guides to GLP-1 cost, GLP-1s without insurance and Medicare GLP-1 coverage explain the other ways people pay.
Are oral GLP-1 medications easier to tolerate than injections?
Not necessarily. A daily pill avoids needles, but the evidence the practice relies on does not show that pills are easier to tolerate. When the Wegovy pill arrived, Matthew Weiner, MD, expected it to bring more side effects and less weight loss than the injection. In his experience, the format of a medication matters far less to people than how much weight they lose, how well they keep it off and how they feel on it.
For that reason the practice does not treat pill versus injection as a question about format alone. When a medication is reviewed, three things are weighed together: how weight is responding, what side effects are showing up, and how the medication fits daily life. A pill that is easy to take but produces a poor response, or an injection that works well but causes intolerable symptoms, both call for a conversation with the prescriber. The Pound of Cure podcast has covered this question in depth.
Do the Wegovy pill and Foundayo work as well with diabetes?
Type 2 diabetes lowers results on every GLP-1, and the pills are no exception. In the Foundayo trial for people with type 2 diabetes, 54% of people on 17.2 mg lost less than 10% of their weight, compared with about 45% in people without diabetes. Diabetes here means an A1c of 6.5% or higher, and the higher the A1c, the less weight people tend to lose.
The practice uses the same poor, typical and super cutoffs with or without diabetes, but people with diabetes should compare their result with the diabetes trial numbers for their drug. Working on blood sugar control with the care team can help the medication work better, often through a whole-food approach like the Metabolic Reset Diet, and any diet change alongside diabetes medicines should be planned with a provider.
Not losing weight on the Wegovy pill or Foundayo? What to do next
Start with time and dose. Someone a few weeks into a lower strength is still stepping up, and a result that looks small may be right on track for the curve. The grade that matters most comes after a full trial at the full dose.
Next, look honestly at nutrition. Eating poorly on a GLP-1 leads to little weight loss and often makes people feel worse, so before anyone calls themselves a non-responder, Matthew Weiner, MD, wants to know how closely the nutrition plan is being followed. Working with the team to tighten nutrition is often the first change, and it takes hands-on support from the registered dietitian team rather than a handout.
If the full dose and a solid nutrition effort still leave the result under 10%, that is a poor response, and it says nothing about willpower. How well a person responds to a GLP-1 is largely driven by DNA, and in Weiner's experience the people who lose the least are often the ones trying the hardest. At that point it is reasonable to ask a provider whether an injectable medication would be a better fit.
At the practice, everyone starts with a GLP-1. Non-responders move toward a surgery conversation sooner, and partial responders get a more flexible plan that may or may not include surgery. Our articles on whether weight loss surgery is better than GLP-1 medications and bariatric surgery in the GLP-1 era cover that conversation, and weight loss surgery in Tucson explains the options. Whether surgery makes sense depends on each person's health and history, which is a decision to make with a provider, and you can book an appointment with Matthew Weiner, MD, and the team.
Frequently asked questions
Is the Wegovy pill as effective as the injection?
In trials, the 25 mg Wegovy pill averaged 13.6% weight loss over 64 weeks, and about 4 in 10 people lost less than 10%. On the 2.4 mg semaglutide injection, about 28% to 34% lost less than 10%, and on the 7.2 mg injection about 20% did. The pill works for many people, but it leaves more people in the poor-response range than the injection.
How much weight can you lose on Foundayo?
In the main trial, people on Foundayo 17.2 mg lost about 11% of their body weight on average over 72 weeks, and 18.4% lost 20% or more. About 45% lost less than 10%. These are group results, and individual results vary widely.
I am on Foundayo 0.8 mg and not losing much. Am I a poor responder?
In most cases it is too early to tell. Foundayo 0.8 mg is the lowest tablet strength and a step on the way up. The practice grades results from 1 month against the time curve, and the result that counts most comes after a full trial at the full dose.
Should I switch from a GLP-1 pill to an injection?
If the result is under 10% after a full trial at the full pill dose and nutrition is on track, it is reasonable to ask a provider whether an injectable medication would fit better. The decision also weighs side effects, cost and daily-life fit, so it belongs in a conversation with the prescriber.